Daniel W Lin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3417835/publications.pdf

Version: 2024-02-01

86 papers	4,370 citations	172386 29 h-index	114418 63 g-index
89 all docs	89 docs citations	89 times ranked	7672 citing authors

#	Article	IF	Citations
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
2	Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. European Urology, 2018, 73, 560-569.	0.9	401
3	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. Journal of Clinical Investigation, 2019, 129, 4492-4505.	3.9	250
4	Prostate cancer â€“ major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 245-253.	157.7	245
5	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 4066-4072.	0.8	234
6	Genomic Markers in Prostate Cancer Decision Making. European Urology, 2018, 73, 572-582.	0.9	201
7	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
8	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 2018, 8, 354-360.	1.1	151
9	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	0.9	151
10	Treatment and survival outcomes in young men diagnosed with prostate cancer. Cancer, 2009, 115, 2863-2871.	2.0	145
11	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. Clinical Cancer Research, 2013, 19, 2442-2450.	3.2	132
12	Ferroptosis as a Novel Therapeutic Target for Friedreichâ€™s Ataxia. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 47-54.	1.3	93
13	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
14	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	3.2	80
15	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROâ€IMPACT study. Cancer, 2017, 123, 2850-2859.	2.0	66
16	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	2.8	61
17	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	1.6	60
18	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. Journal of Urology, 2019, 201, 528-534.	0.2	57

#	Article	IF	Citations
19	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	1.2	55
20	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	0.9	55
21	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canaryâ€“Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	0.9	48
22	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology, 2020, 38, 1549-1557.	0.8	48
23	Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer, 2016, 122, 2168-2177.	2.0	47
24	Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 505.e9-505.e13.	0.8	46
25	The Role of Cyclooxygenase-2 Inhibition for the Prevention and Treatment of Prostate Carcinoma. Clinical Prostate Cancer, 2003, 2, 119-126.	2.1	34
26	Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clinical Epigenetics, 2016, 8, 97.	1.8	34
27	Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. Journal of Clinical Oncology, 2018, 36, 1498-1504.	0.8	34
28	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Annals of Internal Medicine, 2018, 168, 1.	2.0	33
29	Disparities in Access and Regionalization of Care in Testicular Cancer. Clinical Genitourinary Cancer, 2018, 16, e785-e793.	0.9	32
30	Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. Urology, 2015, 86, 262-268.	0.5	31
31	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	0.9	30
32	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 295-302.	2.0	30
33	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	3.4	30
34	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. European Urology, 2019, 76, 268-272.	0.9	28
35	Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology, 2016, 96, 29-34.	0.5	26
36	Role of radical prostatectomy in metastatic prostate cancer: A review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 125-134.	0.8	26

#	Article	IF	Citations
37	Gene expression panel predicts metastaticâ€lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Molecular Oncology, 2017, 11, 140-150.	2.1	24
38	Prostate Cancer Screening in a New Era of Genetics. Clinical Genitourinary Cancer, 2017, 15, 625-628.	0.9	24
39	Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. Journal of Urology, 2017, 198, 1286-1294.	0.2	24
40	Beyond PSA: Utility of novel tumor markers in the setting of elevated PSA. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 315-321.	0.8	22
41	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	2.0	22
42	Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2937-2944.	1.8	21
43	Readability of urologic pathology reports: The need for patient-centered approaches. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1091-1094.	0.8	18
44	Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 92.e11-92.e16.	0.8	18
45	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 4736-4750.	0.4	18
46	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. European Urology, 2018, 73, 706-712.	0.9	17
47	Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. Prostate, 2015, 75, 1354-1362.	1.2	16
48	Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. Urology, 2016, 91, 70-76.	0.5	16
49	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Urology, 2018, , .	0.2	16
50	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. Journal of Clinical Oncology, 2022, 40, 1500-1505.	0.8	16
51	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. Journal of Urology, 2021, 206, 1147-1156.	0.2	14
52	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2017, 197, 1026-1033.	0.2	13
53	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clinical Genitourinary Cancer, 2021, 19, 144-154.	0.9	13
54	Do all men with pathological Gleason score 8â€“10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	1.3	12

#	Article	IF	Citations
55	Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis. Urology, 2016, 96, 148-155.	0.5	12
56	Optimizing the management of castrationâ€resistant prostate cancer patients: A practical guide for clinicians. Prostate, 2020, 80, 1159-1176.	1.2	11
57	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.0	10
58	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science, 2022, 37, 113-119.	0.2	10
59	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. Prostate Cancer and Prostatic Diseases, 2020, 23, 144-150.	2.0	9
60	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer, 2020, 126, 583-592.	2.0	9
61	Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?. Journal of Clinical Oncology, 2021, 39, 13-16.	0.8	9
62	Pathologic Nodal Involvement in Patients With Penile Cancer With Cavernosal Versus Spongiosal Involvement. Clinical Genitourinary Cancer, 2019, 17, e156-e161.	0.9	8
63	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in highâ€risk localized prostate cancer. Prostate, 2021, 81, 418-426.	1.2	8
64	Paracrine Wnt signaling is necessary for prostate epithelial proliferation. Prostate, 2022, 82, 517-530.	1.2	8
65	Measures of survival benefit in cancer drug development and their limitations. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 122-127.	0.8	4
66	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. European Urology, 2021, 79, 141-149.	0.9	4
67	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. Urology, 2021, 149, 154-160.	0.5	4
68	A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 602-617.	0.8	3
69	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 521-527.	0.8	3
70	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	2.0	3
71	Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer. JAMA Oncology, 2021, 7, 59.	3.4	3
72	Active Surveillance: Very Much â€œPreferredâ€•for Low-Risk Prostate Cancer. Journal of Urology, 2022, 207, 262-264.	0.2	3

#	Article	IF	Citations
73	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.2	3
74	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	1.3	3
75	Active Surveillance for Prostate Cancer: A 2020 Vision. European Urology, 2020, 77, 687-688.	0.9	2
76	The changing landscape of urologic oncology: Initiating systemic therapies, interventional skills, and clinical trials. Urologic Oncology: Seminars and Original Investigations, 2012, 30, S1.	0.8	1
77	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e1-496.e8.	0.8	1
78	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. Urology Practice, 2021, 8, 576-582.	0.2	1
79	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.2	1
80	Is prediagnosis PSA velocity predictive of the risk of death from prostate cancer following radical prostatectomy?. Nature Reviews Urology, 2004, 1, 66-67.	1.4	0
81	Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?. Nature Reviews Urology, 2007, 4, 654-655.	1.4	0
82	Editorial Comment. Journal of Urology, 2009, 182, 2720-2720.	0.2	0
83	Preface. Urologic Clinics of North America, 2015, 42, xvii.	0.8	0
84	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncology, 2018, 14, 527-536.	1.1	0
85	Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706â€“12. European Urology, 2018, 74, e151.	0.9	0
86	Reply by Authors. Journal of Urology, 2021, 206, 1156.	0.2	0